Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Metsera in a report issued on Thursday, March 27th. Cantor Fitzgerald analyst P. Agrawal now ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

After an IPO this year, Metsera is making its best effort to catch up to obesity drug giants Eli Lilly and Novo Nordisk.

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...

Metsera ,” said Whit Bernard, CEO. “We advanced MET-097i, our monthly, fully-biased GLP-1 RA injectable, from f ...

Trident's strategic collaboration with e-commerce players Silkoo and Haitu will combine their unique strengths to drive innovation and mutual growth ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

U.S. stock futures were mixed this morning, with the S&P 500 futures gaining around 0.1% on Tuesday. Shares of KB Home KBH ...

Metsera cleared that benchmark Monday, with a jump from 78 to 82 Monday. Please watch the video at Investors.com - How To ...

So far this year, 11 U.S. venture-backed private companies have gone public or agreed to be acquired at valuations of $1 ...